Moderna (MRNA) Operating Expenses (2017 - 2026)

Moderna (MRNA) has reported Operating Expenses for 10 consecutive years, with $960.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses fell 8.48% year-over-year to $960.0 million in Q2 2026; TTM through Jun 2026 was $5.5 billion, a 12.64% decrease from a year earlier, with the FY2025 full-year figure at $5.0 billion, down 30.12% from the prior year.
• Operating Expenses was $960.0 million for Q2 2026 at Moderna, down from $1.8 billion in the prior quarter.
• Over five years, Operating Expenses peaked at $3.8 billion in Q3 2023 and troughed at $960.0 million in Q2 2026.
• A 5-year average of $2.0 billion and a median of $1.9 billion in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 174.07% in 2022 and plunged 49.73% in 2024, its largest moves.
• Over 5 years, Operating Expenses stood at $3.5 billion in 2022, then fell by 19.95% to $2.8 billion in 2023, then fell by 21.14% to $2.2 billion in 2024, then sank by 30.61% to $1.5 billion in 2025, then slumped by 37.46% to $960.0 million in 2026.
• The last three Operating Expenses figures came in at $960.0 million (Q2 2026), $1.8 billion (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.